Drug Trial News

RSS

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

17 May 2021

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai.

17 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

Minorities substantially underrepresented in pancreatic cancer clinical trials

Despite the fact that certain racial and ethnic minorities get pancreatic cancer more often, are diagnosed at a younger age and die sooner, clinical trials fail to include representative proportions of non-White patients at every phase of study, according to research that was selected for presentation at Digestive Disease Week 2021.

14 May 2021

New clinical trial to test possible therapeutics for COVID-19 in hospitalized patients

The Clinical Trials Network of Tennessee (CTN2) at the University of Tennessee Health Science Center has contracted a new clinical trial to test possible therapeutics for COVID-19 in hospitalized patients. This new trial brings the total generated by CTN2 contracts for the university to nearly $7 million.

12 May 2021

Combining two medications doubles gout treatment success, study reveals

By combining two medications, researchers at Michigan Medicine optimized a therapy for people with gout, a condition that causes severe damage and disability if left untreated.

11 May 2021

The "key" to vaccine development depends on virus’ binding to human cells

New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the "key" to that development lies in the way the virus binds to human cells.

11 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.

7 May 2021

Study: Novavax Covid-19 vaccine is efficacious against the B.1.351 South African variant

The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021.

6 May 2021

Benefits of drug research are not being shared equitably among study participants, indicates study

A Yale-led study reveals that new medicines and vaccines approved for use in the United States are often unavailable in countries that hosted their clinical trials, suggesting that the benefits of drug research are not being shared equitably among populations that participate in testing.

6 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

New vaccine candidate provides breakthrough in the fight against malaria

A malaria vaccine candidate tested on children in West Africa has shown an efficacy of around 77 per cent, say scientists, hailing it as a breakthrough in the fight against the disease.

4 May 2021

Study shows a protective association between anticoagulants and COVID-19

In a new study, researchers investigated the association between the use of oral anticoagulants and warfarin in COVID-19 disease outcomes. They published their results in a paper on the medRxiv* preprint server.

3 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen (PSA) levels to either remain stable or decline.

29 Apr 2021

Previous
1
...
58
59
60
61
62
63
64
...
1149
Next

Drug Trial News

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Minorities substantially underrepresented in pancreatic cancer clinical trials

New clinical trial to test possible therapeutics for COVID-19 in hospitalized patients

Combining two medications doubles gout treatment success, study reveals

The "key" to vaccine development depends on virus’ binding to human cells

Combo COVID-flu vaccine protects against current and emerging variants in animal model

CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis

Study: Novavax Covid-19 vaccine is efficacious against the B.1.351 South African variant

Benefits of drug research are not being shared equitably among study participants, indicates study

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

New vaccine candidate provides breakthrough in the fight against malaria

Study shows a protective association between anticoagulants and COVID-19

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate cancer

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News